Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells $2,038,722.95 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 41,095 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $2,038,722.95. Following the completion of the transaction, the chief executive officer owned 562,463 shares in the company, valued at $27,903,789.43. This represents a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ryan Fukushima also recently made the following trade(s):

• On Friday, August 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The stock was sold at an average price of $50.04, for a total value of $1,000,800.00.
• On Monday, August 3rd, Ryan Fukushima sold 23,818 shares of Tempus AI stock. The stock was sold at an average price of $46.19, for a total value of $1,100,153.42.
• On Wednesday, July 8th, Ryan Fukushima sold 33,284 shares of Tempus AI stock. The shares were sold at an average price of $57.39, for a total value of $1,910,168.76.
• On Monday, July 6th, Ryan Fukushima sold 10,000 shares of Tempus AI stock. The shares were sold at an average price of $60.00, for a total value of $600,000.00.

Tempus AI Stock Performance

Shares of Tempus AI stock opened at $72.69 on Friday. The firm has a market cap of $13.12 billion, a PE ratio of -50.48 and a beta of 3.58. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. Tempus AI, Inc. has a 52 week low of $40.77 and a 52 week high of $104.32. The business’s fifty day simple moving average is $52.93 and its 200-day simple moving average is $51.36.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. The firm had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The company’s quarterly revenue was up 21.6% on a year-over-year basis. During the same period last year, the company earned ($0.22) EPS. Equities analysts forecast that Tempus AI, Inc. will post -1.38 earnings per share for the current year.

Tempus AI News Roundup

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target for Tempus AI to $80 from $70 and maintained a “Buy” rating. The higher target strengthens the bullish case and provides a near-term catalyst for the stock. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is building around Tempus AI’s planned approximately $1.5 billion all-stock acquisition of Personalis. The deal could expand Tempus’ genomic-data, cancer-testing and drug-development capabilities, potentially increasing its strategic value in precision medicine. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Merck and Moderna’s cancer-vaccine trial developments have heightened interest in oncology data and genomic testing. The connection to Tempus is indirect, but the news reinforces the company’s cancer-data and personalized-treatment growth narrative. Tempus AI stock move and Merck-Moderna trial news
• Positive Sentiment: Trading activity in TEM call options was unusually high, with reported volume roughly 57% above normal. This indicates bullish speculation and may be amplifying the stock’s momentum, though options activity can also increase volatility.
• Neutral Sentiment: The stock has moved above its 50-day and 200-day moving averages, raising the possibility of momentum buying or a short squeeze. That technical strength could support further gains, but it also increases the risk of a sharp reversal.
• Negative Sentiment: Tempus AI’s CEO, CFO, EVP and chief accounting officer sold shares, with the largest reported transaction involving CEO Eric Lefkofsky. The sales reduced executives’ holdings and may concern investors, but they were conducted under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, making them a weaker bearish signal than discretionary selling.

Analyst Upgrades and Downgrades

TEM has been the subject of a number of recent analyst reports. Lake Street Capital cut shares of Tempus AI to a “hold” rating in a research report on Monday, July 20th. Freedom Capital upgraded shares of Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Weiss Ratings raised shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 12th. Piper Sandler dropped their target price on shares of Tempus AI from $58.00 to $56.00 and set a “neutral” rating for the company in a report on Tuesday, August 4th. Finally, HC Wainwright cut their target price on Tempus AI from $64.00 to $56.00 and set a “buy” rating on the stock in a research report on Monday, August 3rd. Nine analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $65.69.

Hedge Funds Weigh In On Tempus AI

Hedge funds and other institutional investors have recently bought and sold shares of the company. JPL Wealth Management LLC acquired a new position in Tempus AI in the 3rd quarter valued at about $26,000. Los Angeles Capital Management LLC purchased a new position in shares of Tempus AI in the fourth quarter valued at approximately $27,000. EMC Capital Management purchased a new position in shares of Tempus AI in the second quarter valued at approximately $29,000. Harvest Fund Management Co. Ltd acquired a new position in shares of Tempus AI in the third quarter valued at approximately $38,000. Finally, Whittier Trust Co. grew its holdings in shares of Tempus AI by 190.0% in the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after purchasing an additional 570 shares in the last quarter. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.